UK Cost-Effectiveness of Pegcetacoplan Compared with Ravulizumab for Treatment of Paroxysmal Nocturnal Haemoglobinuria - Supplementary materials.docx

<strong>Supplementary Table 1. Estimated utilities based on the Longworth and McKenzie algorithms </strong> <strong>Supplementary Table 2. Key scenario analyses</strong> <strong>Supplementary Table 3. Probability of developing adverse events per cycle </strong> <strong>Supplementary Table 4. Iron overload disutility</strong> <strong>Supplementary Table 5. Number of physician visits/tests per cycle1 and unit healthcare costs</strong> <strong>Supplementary Table 6. Ravulizumab iron chelation costs</strong> <strong>Supplementary Table 7. Intravascular haemolysis breakthrough cost for patients who discontinue pegcetacoplan due to intravascular haemolysis breakthrough</strong> <strong>Supplementary Table 8. Unit costs of managing adverse events</strong> <strong>Supplementary Table 9. OWSA results for the 10 parameters that contribute the largest difference to the NMB for pegcetacoplan versus ravulizumab </strong> <br>